If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
1847 Goedeker (GOED)
PaxMedica (PXMD)
Vistas Media Acquisition (VMACU)
Yucaipa Acquisition (YAC.U)
Rackspace Technology, Inc. (RXT)
GO Acquisition (GOAC.U)
BigCommerce Holdings, Inc (BIGC)
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
Priced IPO
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
Pandion Therapeutics, Inc. (PAND)
ALX Oncology Holdings Inc. (ALXO)
Trean Insurance Group, Inc. (TIG)
Relay Therapeutics, Inc. (RLAY)
GoHealth, Inc. (GOCO)
More companies

Burning Rock Biotech Limited (BNR)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They aim to transform precision oncology and early cancer detection. They are China’s number one NGS-based cancer therapy selection company, as evidenced by the largest market share of 26.7% in China’s NGS-based cancer therapy selection market in terms of number of patients tested in 2019, according to China Insights Consultancy, or CIC. Their cancer therapy selection platform is built upon their advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through their in-hospital model and smaller hospitals through their central laboratory model. Their NGS-based cancer therapy selection test products are used to assist physicians in selecting the most effective therapy for cancer patients. They currently offer 13 NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples. Their core products, including OncoScreen Plus and LungPlasma, perform on par with those of their global peers.
Yusheng Han Leo Li
Employees Founded
753 2014


Address: 601, 6/F, Building 3, Standard Industrial Unit 2, No.7 Luoxuan 4th Road, International Bio Island, Guangzhou, the People’s Republic of China

Telephone: +86 020-3403 7871

Web page:

IPO information

Expected Date 6/12/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $1679.4
Revenues (MM) $48.7
Net Income (Loss) (MM) $-45.0


What do you think will happen with the BNR share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 13.5
Shares Revised (MM) 13.5
Expected offer amount (MM) $195.75
Realized offer amount(MM) $222.75
Morgan Stanley/ BofA Securities/ Cowen
CMBI/ Tiger Brokers

Sector: Healthcare

Tweets about $BNR

Tweets volume:

RT volume:


Google Trends Stats